Floatz logo

MOGAMULIZUMAB

Cutaneous T Cell Lymphoma

University of Michigan Rogel Cancer Centermonoclonal_antibodyPhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
65/ 100
Competitive Position
81/ 100

Competitive context

61 Active assets in the Cutaneous T Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
City of Hope Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

MOGAMULIZUMAB is also rated in:

adult T-cell leukemia/lymphomaDormant
BB
Indicative ·
71 / 100
View asset →
mycosis fungoidesDormant
BB
Indicative ·
65 / 100
View asset →
peripheral T-cell lymphoma, not otherwise specifiedDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →